Therapies against virulence products of staphylococcus aureus and pseudomonas aeruginosa

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 2, 2011, Pages 228-235

  Wiener Kronish, Jeanine P ^a   Pittet, Jean Francois ^b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Kentucky   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

antibiotic resistance; exotoxins; Methicillin resistant S. aureus; Panton Valentine leukocidin (PVL) gene; Pseudomonas aeruginosa; toxins; virulence

Indexed keywords

ADENOSINE DIPHOSPHATE; ALGINIC ACID; ARGININE; ENDOTOXIN; PANTON VALENTINE LEUKOCIDIN; PHENOL; PHOSPHOLIPASE C; PILIN; PROTEIN A; PYOCYANINE; PYOVERDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOLL LIKE RECEPTOR 5;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL FLAGELLUM; BACTERIAL SECRETION SYSTEM; BACTERIAL STRAIN; BACTERIUM ISOLATE; CRITICALLY ILL PATIENT; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; TYPE III SECRETION SYSTEM; VENTILATOR ASSOCIATED PNEUMONIA; VIRULENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; VIRULENCE;

EID: 79955057034     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1275535     Document Type: Article

References (61)

1. David M Z., Daum R S. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010 23 3 616-687
2. Panlilio A L., Culver D H., Gaynes R P. et al, National Nosocomial Infections Surveillance System. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992 13 10 582-586
3. NNIS System. National Nosocomial Infections Surveillance [NNIS] System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003 31 8 481-498
4. Chambers H F. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001 7 2 178-182
5. Herold B C., Immergluck L C., Maranan M C. et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998 279 8 593-598 (Pubitemid 28110205)
6. Lowy F D. Staphylococcus aureus infections. N Engl J Med 1998 339 8 520-532
7. Troillet N, Carmeli Y, Samore M H. et al. Carriage of methicillin-resistant Staphylococcus aureus at hospital admission. Infect Control Hosp Epidemiol 1998 19 3 181-185 (Pubitemid 128506641)
8. Liu C C., Graber C J., Karr M et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin Infect Dis 2008 46 11 1637-1646 (Pubitemid 351706759)
9. Hersh A L., Chambers H F., Maselli J H., Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008 168 14 1585-1591
10. Kaplan S L., Hulten K G., Gonzalez B E. et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005 40 12 1785-1791 (Pubitemid 40799948)
11. Klevens R M., Morrison M A., Nadle J et al, Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007 298 15 1763-1771 (Pubitemid 47598444)
12. Boussaud V, Parrot A, Mayaud C et al. Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus. Intensive Care Med 2003 29 10 1840-1843 (Pubitemid 37373837)
13. Cribier B, Prvost G, Couppie P, Finck-Barbanon V, Grosshans E, Pimont Y. Staphylococcus aureus leukocidin: a new virulence factor in cutaneous infections? An epidemiological and experimental study. Dermatology 1992 185 3 175-180
14. Adem P V., Montgomery C P., Husain A N. et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005 353 12 1245-1251 (Pubitemid 41345946)
15. Baba T, Takeuchi F, Kuroda M et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002 359 9320 1819-1827 (Pubitemid 34607058)
16. Voyich J M., Otto M, Mathema B et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006 194 12 1761-1770 (Pubitemid 44902009)
17. Bubeck Wardenburg J, Bae T, Otto M, Deleo F R., Schneewind O. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 2007 13 12 1405-1406 (Pubitemid 350224232)
18. Bubeck Wardenburg J, Palazzolo-Ballance A M., Otto M, Schneewind O, DeLeo F R. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 2008 198 8 1166-1170
19. Montgomery C P., Boyle-Vavra S, Adem P V. et al. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis 2008 198 4 561-570
20. Löffler B, Hussain M, Grundmeier M et al. Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog 2010 6 1 e1000715
21. Varshney A K., Martinez L R., Hamilton S M. et al. Augmented production of Panton-Valentine leukocidin toxin in methicillin-resistant and methicillin-susceptible Staphylococcus aureus is associated with worse outcome in a murine skin infection model. J Infect Dis 2010 201 1 92-96
22. Goering R V., McDougal L K., Fosheim G E., Bonnstetter K K., Wolter D J., Tenover F C. Epidemiologic distribution of the arginine catabolic mobile element among selected methicillin-resistant and methicillin-susceptible Staphylococcus aureus isolates. J Clin Microbiol 2007 45 6 1981-1984 (Pubitemid 46933939)
23. Wang R, Braughton K R., Kretschmer D et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007 13 12 1510-1514 (Pubitemid 350224240)
24. Diep B A., Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol 2008 16 8 361-369
25. Hongo I, Baba T, Oishi K, Morimoto Y, Ito T, Hiramatsu K. Phenol-soluble modulin alpha 3 enhances the human neutrophil lysis mediated by Panton-Valentine leukocidin. J Infect Dis 2009 200 5 715-723
26. Foster T J. Immune evasion by staphylococci. Nat Rev Microbiol 2005 3 12 948-958 (Pubitemid 43078158)
27. Uhln M B., Guss B, Nilsson B, Gatenbeck S, Philipson L, Lindberg M. Complete sequence of the staphylococcal gene encoding protein A: a gene evolved through multiple duplications. J Biol Chem 1984 259 3 1695-1702 (Pubitemid 14146555)
28. Lorenz U, Lorenz B, Schmitter T et al. Functional antibodies targeting IsaA of Staphylococcus aureus augment host immune response and open new perspectives for antibacterial therapy. Antimicrob Agents Chemother 2011 55 1 165-173
29. National Nosocomial Infection Surveillance System. National Nosocomial Infection Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004 32 8 470-485
30. El Solh A A., Akinnusi M E., Wiener-Kronish J P., Lynch S V., Pineda L A., Szarpa K. Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 2008 178 5 513-519
31. Chastre J, Wolff M, Fagon J Y. et al, PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003 290 19 2588-2598 (Pubitemid 37443289)
32. Diaz M H., Hauser A R. Pseudomonas aeruginosa cytotoxin ExoU is injected into phagocytic cells during acute pneumonia. Infect Immun 2010 78 4 1447-1456
33. Zhuo H, Yang K, Lynch S V. et al. Increased mortality of ventilated patients with endotracheal Pseudomonas aeruginosa without clinical signs of infection. Crit Care Med 2008 36 9 2495-2503
34. Mastropierro R, Bettinzoli M, Bordonali T, Patroni A, Barni C, Manzato A. Pneumonia in a cardiothoracic intensive care unit: incidence and risk factors. J Cardiothorac Vasc Anesth 2009 23 6 780-788
35. Rangel E L., Butler K L., Johannigman J A., Tsuei B J., Solomkin J S. Risk factors for relapse of ventilator-associated pneumonia in trauma patients. J Trauma 2009 67 1 91-95, discussion 95-96
36. Chenoweth C E., Washer L L., Obeyesekera K et al. Ventilator-associated pneumonia in the home care setting. Infect Control Hosp Epidemiol 2007 28 8 910-915 (Pubitemid 47218268)
37. Yang K, Zhuo H, Guglielmo B J., Wiener-Kronish J P. Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: the role of endotracheal aspirate surveillance cultures. Ann Pharmacother 2009 43 1 28-35
38. O'Toole G A., Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 1998 30 2 295-304 (Pubitemid 28480181)
39. Fleiszig S M., Arora S K., Van R, Ramphal R. FlhA, a component of the flagellum assembly apparatus of Pseudomonas aeruginosa, plays a role in internalization by corneal epithelial cells. Infect Immun 2001 69 8 4931-4937 (Pubitemid 32674475)
40. Wolfgang M C., Jyot J, Goodman A L., Ramphal R, Lory S. Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients. Proc Natl Acad Sci U S A 2004 101 17 6664-6668 (Pubitemid 38586031)
41. Hahn H P. The type-4 pilus is the major virulence-associated adhesin of Pseudomonas aeruginosaa review. Gene 1997 192 1 99-108 (Pubitemid 27276891)
42. Augustin D K., Song Y, Baek M S. et al. Presence or absence of lipopolysaccharide O antigens affects type III secretion by Pseudomonas aeruginosa. J Bacteriol 2007 189 6 2203-2209 (Pubitemid 46411334)
43. Kipnis E, Guery B P., Tournoys A et al. Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury. Shock 2004 21 5 444-451
44. Bleves S, Viarre V, Salacha R, Michel G P., Filloux A, Voulhoux R. Protein secretion systems in Pseudomonas aeruginosa: a wealth of pathogenic weapons. Int J Med Microbiol 2010 300 8 534-543
45. Hauser A R. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 2009 7 9 654-665
46. Berra L, Sampson J, Wiener-Kronish J. Pseudomonas aeruginosa: acute lung injury or ventilator-associated pneumonia? Minerva Anestesiol 2010 76 10 824-832
47. Wojciak-Stothard B, Tsang L Y., Haworth S G. Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 2005 288 4 L749-L760 (Pubitemid 40404144)
48. Sato H, Feix J B., Frank D W. Identification of superoxide dismutase as a cofactor for the pseudomonas type III toxin, ExoU. Biochemistry 2006 45 34 10368-10375 (Pubitemid 44384812)
49. Ganter M T., Roux J, Su G et al. Role of small GTPases and alphavbeta5 integrin in Pseudomonas aeruginosa-induced increase in lung endothelial permeability. Am J Respir Cell Mol Biol 2009 40 1 108-118
50. Sayner S L., Frank D W., King J, Chen H, VandeWaa J, Stevens T. Paradoxical cAMP-induced lung endothelial hyperpermeability revealed by Pseudomonas aeruginosa ExoY. Circ Res 2004 95 2 196-203 (Pubitemid 38988686)
51. Sayner S L., Alexeyev M, Dessauer C W., Stevens T. Soluble adenylyl cyclase reveals the significance of cAMP compartmentation on pulmonary microvascular endothelial cell barrier. Circ Res 2006 98 5 675-681
52. Winson M K., Camara M, Latifi A et al. Multiple N-acyl-L-homoserine lactone signal molecules regulate production of virulence determinants and secondary metabolites in Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 1995 92 20 9427-9431
53. Gambello M J., Iglewski B H. Cloning and characterization of the Pseudomonas aeruginosa lasR gene, a transcriptional activator of elastase expression. J Bacteriol 1991 173 9 3000-3009
54. Pesci E C., Milbank J B., Pearson J P. et al. Quinolone signaling in the cell-to-cell communication system of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 1999 96 20 11229-11234 (Pubitemid 29487363)
55. Mah T F., Pitts B, Pellock B, Walker G C., Stewart P S., O'Toole G A. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003 426 6964 306-310 (Pubitemid 37463151)
56. Flanagan J L., Brodie E L., Weng L et al. Loss of bacterial diversity during antibiotic treatment of intubated patients colonized with Pseudomonas aeruginosa. J Clin Microbiol 2007 45 6 1954-1962 (Pubitemid 46933932)
57. Sawa T, Yahr T L., Ohara M et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999 5 4 392-398 (Pubitemid 29180576)
58. Neely A N., Holder I A., Wiener-Kronish J P., Sawa T. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Burns 2005 31 2 153-158 (Pubitemid 40430869)
59. Baer M, Sawa T, Flynn P et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 2009 77 3 1083-1090
60. Arnoldo A, Curak J, Kittanakom S et al. Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen. PLoS Genet 2008 4 2 e1000005 [Erratum in: PLoS Genet. 2008 Apr;4(4). doi: 10.1371/annotation/76d35829-07a2-479f-bbc1-cce6755b6d8c. Merrill, Rod A corrected to Merrill, A Rod]
61. Bir N, Lafargue M, Howard M et al. Cytoprotective-selective activated Protein C attenuates P. aeruginosa -induced lung injury in mice. Am J Respir Mol Cell Biol 2011 January 21 [Epub ahead of print]